Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for Tsha-102 in Rett Syndrome Enabled by Irsf Natural History Data and Positive Clinical Data From Part a of the Reveal Adult/Adolescent and Pediatric Trials Evaluating Tsha-102

THOMSON REUTERS
29 May

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for Tsha-102 in Rett Syndrome Enabled by Irsf Natural History Data and Positive Clinical Data From Part a of the Reveal Adult/Adolescent and Pediatric Trials Evaluating Tsha-102

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10